UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 2015
AEOLUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
0-50481
|
|
56-1953785
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
26361 Crown Valley Parkway, Suite 150
Mission Viejo, California 92691
(Address of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s Telephone Number, Including Area Code)
__________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On March 31, 2015, Aeolus Pharmaceuticals, Inc. (the “Company”) exported its experimental lead compound, AEOL 10150 to Rafa Laboratories, Ltd., a pharmaceutical company based in Jerusalem, Israel. The drug product was manufactured under the Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the United States Department of Health and Human Services, and exported with its permission and in compliance with applicable Federal law. The drug product was exported for testing that is not part of the development program outlined in its contract with BARDA.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 4, 2015 | AEOLUS PHARMACEUTICALS, INC. |
| /s/ David C. Cavalier | |
| Chairman & Chief Financial Officer |